The discovery and development of GLP-1 receptor agonists for type 2 diabetes and obesity is a bench-to-bedside success story.1 Multiple GLP-1 receptor agonists are now in clinical use, such as ...

Estimated geographical and temporal distribution of lung-cancer incidence varied across the four main subtypes worldwide. Our ...

Since the first, seminal randomised controlled trial (RCT) in inflammatory bowel disease (IBD) in 1955,1 the central tenets ...

All physicians are faced with the challenge of how to help patients with no approved therapies for their diseases. What are ...

Artificial intelligence (AI) for mammography is an early exemplar of the integration of AI systems into clinical pathways and ...

The global incidence of cancer reached 20 million in 2022 and is projected to rise to 33·1 million by 2050.1 Amid the growing ...

We would like to thank Nikolas Ruffer and Martin Krusche for their considered Correspondence; their letter raised an important point regarding the nomenclature used in our case report. The authors ...

Existing treatment criteria for chronic hepatitis B virus (HBV) infection are mainly based on data from observational studies, such as the REVEAL study from Taiwan, which was initiated in the early ...

A 58-year-old male patient presented to the dermatology clinic at West China Hospital of Sichuan University (Chengdu, Sichuan ...

We read with interest the article by Marie Lund and colleagues published in The Lancet Oncology investigating the association ...

The announcement by US President Donald Trump that the USA will withdraw from WHO1 will leave both a large financial gap and ...

The phase 2 REST trial by Frida Bugge Askeland and colleagues, reported in The Lancet Haematology, provides insight into ...